Alcon to Acquire STAAR Surgical for $1.5B in Cash Transaction

Alcon has agreed to acquire STAAR Surgical for $1.5 billion in a cash transaction, with a purchase price of $28 per share, representing a 59% premium to STAAR's 90-day average share price. The acquisition will expand Alcon's ophthalmic surgical portfolio and strengthen its position in the global eye care market. The deal is expected to close in the second half of 2023.

In a significant move to bolster its presence in the global eye care market, Alcon Inc. has agreed to acquire STAAR Surgical Company in a cash transaction valued at $1.5 billion. The acquisition, announced on July 2, 2025, will see Alcon pay $28 per share for STAAR, representing a 59% premium to the latter's 90-day average share price [2]. The deal is expected to close in the second half of 2023, subject to regulatory and shareholder approvals.

This strategic acquisition will expand Alcon's ophthalmic surgical portfolio, integrating STAAR's refractive lens and surgical technology into Alcon's offerings. The combined entity will be well-positioned to provide comprehensive treatments across the spectrum of myopia and other vision loss conditions [2]. The deal is anticipated to be accretive to Alcon's earnings in the second year following the acquisition [2].

Alcon, a Swiss-American medical firm specializing in eye care, was spun out from Novartis in 2019. The acquisition of STAAR aligns with Alcon's strategy to consolidate its market position and offer a broader range of ophthalmic surgical solutions. STAAR's board has recommended the transaction to shareholders, citing the significant premium and potential value that exceeds STAAR's standalone strategy [2].

The global ocular implant market is experiencing steady advancements, driven by technological innovations and increasing prevalence of ocular disorders such as cataracts, glaucoma, and retinal diseases. The market size is estimated to be valued at USD 2.15 billion in 2025 and is expected to reach USD 2.70 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.3% from 2025 to 2032 [3]. This growth is fueled by rising demand in aging populations and increasing awareness about vision restoration therapies worldwide.

The acquisition of STAAR will not only enhance Alcon's product offerings but also strengthen its competitive position in the rapidly growing ocular implant market. The integration of STAAR's technology will allow Alcon to provide more advanced and comprehensive eye care solutions, catering to a broader range of patient needs.

References:
[1] https://www.marketscreener.com/news/alcon-inc-agreed-to-acquire-staar-surgical-company-for-1-4-billion-ce7c5edbdf8cf321
[2] https://uk.finance.yahoo.com/news/alcon-buy-eye-health-firm-054606011.html
[3] https://www.openpr.com/news/4132211/ocular-implant-market-generated-opportunities-and-future